composite cultured skin

composite cultured skin

Dermatology A skin substitute used to cover burn wounds and epidermolysis bullosa. See Artificial skin.
Mentioned in ?
References in periodicals archive ?
of New York is a publicly traded (Nasdaq: ORTC) company that has developed and patented a product called Composite Cultured Skin, which is used to stimulate the repair and regeneration of human skin, particularly in burn victims.
Composite cultured skin (CCS) is composed of human skin cells, which are derived from infant foreskin and placed on a porous collagen scaffold.
Ortec's current focus is the application of its Composite Cultured Skin (CCS) product to heal chronic and acute wounds.
Ortec International, New York, NY, announced it has received permission from the Food and Drug Administration (FDA) to begin a pivotal study of its patented Composite Cultured Skin (CCS) to close "donor site" wounds of burn victims.
NASDAQ: ORTC) announced today that it has adopted the trade name OrCel(TM) for its Composite Cultured Skin (CCS) product.
Food and Drug Administration (FDA) that its Composite Cultured Skin (CCS) product has been placed on the agenda for review by the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee scheduled for July 17th, 2001.
NASDAQ: ORTC) announced today that it's lead product, Composite Cultured Skin (CCS), will be introduced to the wound healing community at The 14th Annual Symposium on Advanced Wound Care and Medical Research Forum on Wound Repair being held in Las Vegas, Nevada, which will take place April 30th through May 3rd, 2001.
NASDAQ: ORTC) announced today that the recent approval of its Composite Cultured Skin (CCS) product by the Food and Drug Administration's (FDA) was featured in the April 4th, 2001 edition of the Journal of American Medical Association (JAMA) (Volume 285, No.
Nasdaq:ORTC) announced today that the Food and Drug Administration (FDA) has accepted the company's filing of a Pre-Market Approval (PMA) application for its Composite Cultured Skin (CCS) tissue-engineered product submitted to the FDA on March 5, 2001.
Kodiyalam will be directly responsible for planning and implementing the marketing and distribution initiatives for commercialization of Ortec's Composite Cultured Skin (CCS) product.
Ortec's Chairman and CEO, stated that "Ortec is still in the development stage and its financial operations in 2000 were consistent with management's projections as to use of cash needed for the development and clinical trials of the Company's Composite Cultured Skin (CCS) for the treatment of skin wounds resulting from venous and diabetic ulcers, donor sites and epidermolysis bullosa.
NASDAQ: ORTC) announced today that it will file four additional patents with the United States patent office further enhancing and broadening the proprietary aspects of its Composite Cultured Skin (CCS) technology.